子宮頸癌の放射線治療後の予後に関与する6p21.2 LOH,18q21.2 LOHとHPV感染

抄録

Studies of loss of heterozygosity (LOH) in cervical carcinoma have reported a high frequency of allelic deletions affecting 3p21.3,6p21.2,17p13.1, and 18q21.2. Our study explored whether human papilloma virus (HPV)and LOH on chromosome 3p21.3,6p21.2,17p13.1, and 18q21.2 are associated with treatment outcome in patients with cervical cancer after radiotherapy. A total of 65 patients with cervical cancer (stage I-ive patients, II-eight, III-34, IV-16, recurrence-two) were included in this study. Tumors and normal DNA were analyzed by polymerase chain reaction (PCR) for genetic losses at ten polymorphic microsatellite loci. The presence of HPV and its type were analyzed by PCR-based assay using the consensus primers for L1 and E6 region. Chromosomes 3p21.3,6p21.2,17p13. land 18q21.2 were involved in the LOH in 23.1%,41.5%%,33.8%, and 23.1% of the informative carcinomas, respectively. HPV-positive tumors were found in 73.8% of the patients. Overall survival was significantly worse for the patients with LOH on chromosome 6p21.2 and 18q21.2 as compared to those without LOH (P=0.006, and P=0.007, respectively). The HPV-negative patients survived significantly shorter compared to the HPV-positive patients in the overall survival (P=0.01). The results of this study suggest that absence of HPV infection, LOH on 6p21.2, and LOH on 18q21.2 are the most important determinants of outcome of patients with cervical carcinoma after radiotherapy.